Shots:
- Eli Lilly has entered into a definitive agreement to acquire AtaiBeckley, incl. its asset, BPL-003 (mebufotenin benzoate) & VLS-01 (buccal film formulation of DMT) to treat treatment-resistant depression; closing expected in Q3’26
- Lilly will acquire AtaiBeckley for $6.75/share, plus a CVR of ~$2.5/share tied to development & regulatory milestones for BPL-003 & VLS-01. The deal represents ~$2.8B upfront equity value & up to ~$1B in CVR payments
- CVR holders may receive $1.00 upon VLS-01 P-III initiation within 4yrs. of closing, $0.5 upon US FDA approval & DEA rescheduling of BPL-003 within 5yrs., & $1 upon US FDA approval & DEA rescheduling of VLS-01 within 7yrs. of closing
Ref: PRnewswire | Image: AtaiBeckley | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us atconnect@pharmashots.com
